PF-06651600 + PF-06651600 + PF-06651600 + PF-06651600 + PF-06651600 + placebo + PF06700841
Phase 2Completed 0 watching 0 views this week⚡ Active
51
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Active Non-segmental Vitiligo
Conditions
Active Non-segmental Vitiligo
Trial Timeline
Nov 26, 2018 → Feb 5, 2021
NCT ID
NCT03715829About PF-06651600 + PF-06651600 + PF-06651600 + PF-06651600 + PF-06651600 + placebo + PF06700841
PF-06651600 + PF-06651600 + PF-06651600 + PF-06651600 + PF-06651600 + placebo + PF06700841 is a phase 2 stage product being developed by Pfizer for Active Non-segmental Vitiligo. The current trial status is completed. This product is registered under clinical trial identifier NCT03715829. Target conditions include Active Non-segmental Vitiligo.
Hype Score Breakdown
Clinical
17
Activity
12
Company
9
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03715829 | Phase 2 | Completed |
Competing Products
20 competing products in Active Non-segmental Vitiligo